An interesting phenomenon is that the ETF drops from a peak height to the bottom 480-500 BARS daily, weekly every 100 BARS, monthly every 23 BARS.
According to the calculation it is supposed to jump up by February 22nd.
The last decline cycle from March 2020 is the strongest and the volumes are much larger ....... it may cause the jump up to be more...
Hysteria of the large funds that hold shorts causes a drop in price and panic.
Anyone who looks at MRNA can see exactly the same pattern of action in April 2020.
After approval from the World Health Organization there is no reason to move down
No financial advice!
however it is difficult to do technical analysis for this ETF.
And all the contracts on volatility seem to be in ok order.
As soon as the spring will released it will fly.
Not professional advice. Idea only
post covid therapy treatment
Big Market value potential
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.
Idea only not professional advice
BIOLASE Reports 70% Revenue Growth In First Quarter 2021; Continued High Demand From New Users For Dental Lasers.
2021 First Quarter Operating Highlights (all comparisons are on a year over year basis):
Net revenue grew 70% to $8.1 million with:
Laser system sales increased 139%
Consumables and other revenue increased...
All the indicators show that something could happen at any moment ...
Inflation is starting to climb.
The virus is still here.
The economic situation on the street is the opposite of the stock market.
A lot of money has come out of assets in the last month.
The Fed in a last-ditch effort is holding the market, the “reassuring” messages.
the VIX fear index is...
Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors.
In addition to the Sepsis for which it was developed, the drug Allocetra has other applications such as severe patients with Covid 19 '
Indication Global Market Size Pre Clinical Phase ...
The drug Allocetra saves the lives of patients in a severe condition from the virus in Israel.
The end of the Phase 2 trial is about to be published soon.
preventing or treating complications associated with sepsis, COVID-19, bone-marrow transplants and solid tumors.
At the end of 2021, the drug report on patients will be published.
Last chance before takeoff.
Sepsis is currently the number three cause of death in the Western world, after heart-lung failure and cancer. This is a market of more than $ 30 billion.
The Enlv product was originally intended for the treatment of sepsis (sepsis) and is in 2nd place in drug trials. The drug developed by Enlv is supposed to over-activate the immune system in patients with...
Loading ammunition for the next rally.
The cannabis field is going to be the hottest market (it has been dehydrated for a long time).
The company's reports are not the best but improving quarter by quarter.
The big money will come from investments that have come out of technology stocks that have risen hundreds of percent upwards (and will probably...
AIM ImmunoTech Announces IRB Approval to Enroll COVID-19 ‘Long Haulers’ in the AMP-511 ME/CFS Clinical Trial of Ampligen.
Many survivors of the first SARS-CoV-1 epidemic in 2003 continued to report classic chronic fatigue-like symptoms after recovering from the acute illness. In fact, approximately 27% of survivors met the CDC criteria for chronic fatigue...